2016 June

After just returning from the 2016 American Society of Clinical Oncology meeting in Chicago, it was clear that there is a palpable excitement over recent progress in cancer research and therapeutic drug development.

As I write this, the 2016 ASCO conference has just concluded in Chicago. And, as is typical with this event, the amount and level of groundbreaking research and information presented at this year's conference is nothing less than staggering in its scope, innovation, and promise.

Breast cancer has traditionally not been viewed as immunogenic. There is now a growing body of evidence that immune infiltration has a prognostic role in al breast cancer subtypes, and predicts improved clinical outcome in triple-negative and human epidermal growth factor receptor 2-positive tumors.

The purpose of this retrospective study is to evaluate tumor response rates and toxicity profiles of IL-2 therapy in a more contemporary cohort of patients with metastatic melanoma and a history of brain metastases.

Review of the currently available and approved therapeutic agents for the management of metastatic squamous cell NSCLC and clinical trials focusing on targeted therapy.